These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 11313683)

  • 41. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The helper T lymphocyte precursor (HTLp) frequency does not predict outcome after HLA-identical sibling donor G-CSF-mobilised peripheral blood stem cell transplantation.
    Healey G; Schwarer AP
    Bone Marrow Transplant; 2002 Sep; 30(6):341-6. PubMed ID: 12235517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in children with hematological diseases: a single center pilot study.
    Benito AI; Gonzalez-Vicent M; Garcia F; Balas A; Quintero V; Madero L; Vicario JL; Diaz MA
    Bone Marrow Transplant; 2001 Sep; 28(6):537-43. PubMed ID: 11607765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation.
    Cetkovský P; Koza V; Jindra P; Skopek P; Svojgrová M
    Bone Marrow Transplant; 1997 Oct; 20(8):639-41. PubMed ID: 9383226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
    Urbano-Ispizua A; Solano C; Brunet S; Hernández F; Sanz G; Alegre A; Petit J; Besalduch J; Vivancos P; Díaz MA; Moraleda JM; Carreras E; Ojeda E; de la Rubia J; Benet I; Domingo-Albós A; García-Conde J; Rozman C
    Bone Marrow Transplant; 1996 Jul; 18(1):35-40. PubMed ID: 8831993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
    Stinson TJ; Adams JR; Bishop MR; Kruse S; Tarantolo S; Bennet CL
    Bone Marrow Transplant; 2000 Sep; 26(6):663-6. PubMed ID: 11041569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic peripheral blood stem cell transplantations in children--a single center experience.
    Sufliarska S; Horáková J; Bodová I; Martinka J; Hrubisko M; Kovács L; Jancovicová K; Lukác J
    Neoplasma; 2004; 51(2):110-6. PubMed ID: 15190420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome.
    Martín C; Torres A; León A; Rubio V; Alvarez MA; Herrera C; Jean-Paul E; Correa MA; Rojas R; Campos R; Serrano J; Romero R; Román J; Guzmán JL; Flores R; Falcón M; Martínez F; Gómez P
    Bone Marrow Transplant; 1998 Feb; 21(4):375-82. PubMed ID: 9509972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults.
    Ojeda E; Garcia-Bustos J; Aguado M; Arrieta R; Quevedo E; Yuste VJ; Canales M; Hernandez-Navarro F
    Bone Marrow Transplant; 1999 Sep; 24(6):601-7. PubMed ID: 10490724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: a single-center experience.
    Takenaka K; Shinagawa K; Sunami K; Fujii N; Hiramatsu Y; Maeda Y; Nawa Y; Katayama Y; Teshima T; Ishimaru F; Kiura K; Ikeda K; Harada M
    Int J Hematol; 2000 Oct; 72(3):362-70. PubMed ID: 11185996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial.
    Ciernik IF; Schanz U; Gmür J
    Bone Marrow Transplant; 1999 Jul; 24(2):147-51. PubMed ID: 10455342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study.
    Valcárcel D; Sanz MA; Sureda A; Sala M; Muñoz L; Subirá M; Laborda R; Clopés A; Sierra J
    Bone Marrow Transplant; 2002 May; 29(9):783-7. PubMed ID: 12040477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT.
    Solano C; Martinez C; Brunet S; Tomás JF; Urbano-Ispizua A; Zuazu J; Ojeda E; Bargay J; Moraleda JM; Bailen A; Sierra J; García-Conde J; Rozman C
    Bone Marrow Transplant; 1998 Dec; 22(12):1129-35. PubMed ID: 9894714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
    Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
    Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hematologic recovery in patients who are treated with autologous stem cells transplantation taken from bone marrow after granulocyte-colony-stimulating factor stimulation.
    Gawronski K; Rzepecki P; Oborska S; Wasko-Grabowska A
    Transplant Proc; 2011 Oct; 43(8):3114-5. PubMed ID: 21996240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A comparative study of unrelated donor bone marrow transplantation and peripheral blood stem cell transplantation for their therapeutic effects on leukemia].
    Fan ZP; Yang K; Liu QF; Sun J; Xu D; Zhang Y; Wei YQ; Ye CX; Jiang QL; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1494-7, 1512. PubMed ID: 17062361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.